AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01316302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, taken QD for 12 weeks.
Trial: NCT02194621
Drug: Placebo toothpaste: Crest Cavity Protection toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
Trial: NCT00443430
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
Trial: NCT00184912
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04947566
Drug: Comparison of Efficacy of Naproxen versus Ibuprofen
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
Trial: NCT00053846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03616769
Drug: antiplatelet drugs ,statins ,antihypertensive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the international guidelines, we treated patients who suffered from different disease.
Trial: NCT03837756
Drug: 3BNC117 and 10-1074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Trial: NCT03008590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule each evening
Trial: NCT00829166
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Trial: NCT04408092
Drug: Granulocyte Macrophage Colony Stimulation Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
Trial: NCT02084134
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg at the time of surgery
Trial: NCT04436510
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily
Trial: NCT00841295
Drug: Parenteral L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
Trial: NCT01328288
Drug: standard ART according to the Thai Ministry of Public Health national guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Trial: NCT02332031
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
Trial: NCT00659334
Drug: Ferumoxtran-10 (Combidex)
RxNorm normalized name: acetaminophen / caffeine / phenyltoloxamine citrate / salicylamide Oral Capsule [Combiflex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 mg/kg
Trial: NCT00607646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
Trial: NCT04514367
Drug: ANX005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT01879748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)
Trial: NCT00003667
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003667
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02559232
Drug: Direct Oral Anticoagulant (DOAC)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment pattern following the summary of product characteristics
Trial: NCT03485365
Drug: GSK3858279 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3858279 will be available as solution for injection to be administered via IV route.
Trial: NCT03485365
Drug: GSK3858279 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3858279 will be available as solution for injection to be administered via SC route.
Trial: NCT03485365
Drug: Placebo matching to GSK3858279 (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as sodium chloride solution to be administered via SC route.
Trial: NCT01798316
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
Trial: NCT01798316
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care pain management regimen, no IV Acetaminophen,
Trial: NCT02699515
Drug: MSB0011359C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Trial: NCT00204893
Drug: calcium formate
RxNorm normalized name: Calcium formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
Trial: NCT00814073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03787368
Drug: BAY1213790
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of BAY1213790 (Two different doses)
Trial: NCT04359823
Drug: Lovastatin 2%, 2% Cholesterol Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Trial: NCT04359823
Drug: Lovastatin 2% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Trial: NCT00452101
Drug: Aquamin F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03866993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT02219555
Drug: Steroid Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: volume and specific steroid drug will be based on the recommendation of the treating clinician
Trial: NCT04450355
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous normal saline infusion
Trial: NCT00384930
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth one a day for twelve weeks
Trial: NCT03978494
Drug: Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
Trial: NCT01879605
Drug: Docusate natrium and sorbitol
RxNorm normalized name: docusate / sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089843
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch 150mcg daily
Trial: NCT00089843
Drug: Placebo Actonel (risedronate)
RxNorm normalized name: risedronate Oral Tablet [Actonel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet identical in appearance to active Actonel (risedronate) tablet
Trial: NCT00089843
Drug: Placebo testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch identical in appearance to testosterone patch
Trial: NCT01386580
Drug: 2B3-101 60 mg/m2 every 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV every 28 days
Trial: NCT01386580
Drug: 2B3-101 50 mg/m2 every 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV every 21 days
Trial: NCT00921505
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet ibuprofen 400 mg oral single dose (1 tablet)
Trial: NCT00921505
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets (2 x 600 mg) oral single dose (2 tablets)
Trial: NCT00921505
Drug: Paracetamol + ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
Trial: NCT01392989
Drug: CIK cells
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT04420871
Drug: 150 mg of capecitabine
RxNorm normalized name: capecitabine 150 MG
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
Trial: NCT03940651
Drug: General Anesthetics
RxNorm normalized name: GENERAL ANESTHETICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to type of anesthesia
Trial: NCT02361242
Drug: PXT00864
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Trial: NCT03218852
Drug: prednisone and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone and cyclophosphamide are both administered to participants in this group.
Trial: NCT00589888
Drug: Intralipid 20% @ 20cc/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
Trial: NCT00589888
Drug: Intralipid 20%@ 40cc/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
Trial: NCT00589888
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
Trial: NCT03800706
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
Trial: NCT04492956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02388529
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Trial: NCT02388529
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Trial: NCT02388529
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Trial: NCT02388529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Trial: NCT03613090
Drug: Collagen-hydroxyapatite scaffold (Syn-Oss)
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
Trial: NCT03613090
Drug: Collagen Scaffold (Colla-Plug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
Trial: NCT00559052
Drug: VIOKASE 16
RxNorm normalized name: Viokase 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
Trial: NCT00428506
Drug: albumin 4 gr/L ascites removed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumin 4 gr/L ascites removed
Trial: NCT00428506
Drug: albumin 8 gr/L ascites removed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumin 8 gr/L ascites removed
Trial: NCT01857843
Drug: Ezetimibe 10mg & Simvastatin 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Trial: NCT01857843
Drug: Pravastatin 20mg
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Trial: NCT04221906
Drug: BOS-475
RxNorm normalized name: BOS TAURUS EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream
Trial: NCT01492647
Drug: JNJ 10229570-AAA 1.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Trial: NCT01492647
Drug: JNJ 10229570-AAA 3.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Trial: NCT04312113
Drug: Adipose derived, autologous mesenchymal stem cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
Trial: NCT02752087
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03066817
Drug: Propylene Glycol
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50cc of propylene glycole will be given to participants as one-time dose, used as placebo
Trial: NCT01286844
Drug: GSK2190915A 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral powder for dispersion in water
Trial: NCT01286844
Drug: GSK2190915A 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral powder for dispersion in water
Trial: NCT01286844
Drug: GSK2190915A 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral powder for dispersion in water
Trial: NCT01286844
Drug: GSK2190915A 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral powder for dispersion in water
Trial: NCT01286844
Drug: GSK2190915A 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral powder for dispersion in water
Trial: NCT00069095
Drug: Leucovorin 200 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
Trial: NCT00069095
Drug: Fluorouracil 400 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005653
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT02660424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00543751
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03384290
Drug: PRS-060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT03384290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS-060 Matching Placebo
Trial: NCT02794493
Drug: Traditional Chinese Medicine Formula LC09
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01750268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00025259
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00025259
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03321292
Drug: L-arginine 1000 mg and Acetylesalicylic acid75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
Trial: NCT03321292
Drug: acetylsalicylic acid 75 mg
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Trial: NCT02399475
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
Trial: NCT02399475
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
Trial: NCT01476332
Drug: cis-urocanic acid 0,5% eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Trial: NCT01476332
Drug: cis-urocanic acid 2.5% eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Trial: NCT01476332
Drug: Placebo for cis-UCA, eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Trial: NCT00003859
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02682888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo